Retrovirology

official impact factor 5.24
Search for
Advanced search
Retrovirology
Tools

This article is part of the supplement: AIDS Vaccine 2009

Open Access Oral presentation

OA01-06 LB. HIV-1 plasma RNA and risk of HIV-1 transmission

JR Lingappa1*, JP Hughes1, D Donnel2, JM Baeten1, JI Mullins1, MS Campbell1, GE Gray3, M Essex4, C Farquhar1, H Rees3, A Wald1, L Corey1 and C Celum1

  • * Corresponding author: JR Lingappa

Author Affiliations

1 University of Washington, Seattle, Washington, USA

2 Fred Hutchinson Cancer Research Centre, Seattle, USA

3 University of the Witwatersrand, Johannesburg, South Africa

4 Harvard University, Boston, USA

For all author emails, please log on.

Retrovirology 2009, 6(Suppl 3):O12 doi:10.1186/1742-4690-6-S3-O12

Published: 22 October 2009

First paragraph (this article has no abstract)

Non-sterilizing HIV-1 vaccines may provide public health benefits if they significantly reduce plasma HIV-1 RNA, thus potentially reducing infectiousness. Quantification of reduction in plasma HIV-1 RNA needed to decrease HIV-1 transmission is useful for design of efficacy trials of candidate HIV-1 vaccines. We modeled the relationship between plasma HIV-1 RNA and HIV-1 transmission using data from a prospective study of African heterosexual HIV-1 serodiscordant couples.